CVC adds analytical services to its offering
The new division, which is kitted out with high performance liquid chromatography (HPLC) machines and analysis tools, will provide drugmakers with multi-vector design and experiment development services that the firm believes will prove invaluable for companies seeking to expedite operations in an increasing competitive market.
As Venepalli explained analytical chemistry problems are some of the most difficult that pharmaceutical firms are likely to encounter as they look to produce new drugs, particularly in areas such as method development, validation and remediation challenges.
He added that CiVentiAnalytical would work synergistically with the new active pharmaceutical ingredient (API) and intermediate manufacturing plant that the firm recently added in Hyderabad, India to conduct large volume manufacturing runs for its industrial clients.
In common with many within the contracting sector, CiVentiChem’s hope is that the expansion will allow it provide services covering early R&D to full clinical development and that this will help it build and expand its worldwide customer base.
Venepalli explained that: “With modern laboratories in the US and a lab and pilot plant in India, we have an attractive and unique business model,” adding that customer have “the luxury of choosing to work with [the firm] either in the US or in India based on their project needs.”